Navigation Links
VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
Date:5/25/2011

nal study report will be submitted to the FDA upon completion.  VIVUS expects to file the NDA for avanafil in the second quarter of 2011.

About the StudyTA-303 was a randomized, double-blind, placebo-controlled, parallel group, multicenter study of the safety and efficacy of avanafil in the treatment of erectile dysfunction following bilateral, nerve-sparing, radical prostatectomy in 298 men with ED.  On average, subjects entering the study were 58 years old, 19 months past their surgery dates and diagnosed with severe ED.  Subjects were randomized to 100mg or 200mg avanafil or placebo and were instructed to take one dose of study drug 30 minutes prior to initiation of sexual activity.  The study had a four-week run-in period followed by 12 weeks of treatment.  The primary endpoints of the study were improvement in erectile function as measured by the SEP2 and SEP3 and improvements in the EF-Domain of the IIEF score; secondary endpoints included patient satisfaction with erections and with sexual experience.

About the Avanafil Phase 3 ProgramIn addition to TA-303, the avanafil phase 3 program consists of three pivotal studies:  TA-301 (REVIVE), TA-302 (REVIVE-Diabetes), and TA-314. TA-301 and TA-302 were randomized, double-blind, placebo-controlled phase 3 studies of avanafil in 646 and 390 men, respectively, with a history of ED for at least six months. Each of these trials had a similar trial design with patients undergoing a four-week, non-treatment run-in period followed by 12 weeks of treatment. Primary endpoints of the studies are improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the EF Domain score of the International Index of Erectile Function (IIEF). In both the TA-301 and TA-302 studies, all doses of avanafil met the primary endpoints, with successful intercourse achieved by some subjects as early as 15 minutes after dosing. TA-314 was an open
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
11. VIVUS to Present at the 10th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Platelets, the tiny cell fragments whose job it is ... a cell nucleus. But they can "feel" the physical ... have discovered. , Platelets respond to surfaces with greater ... they "turn on" other platelets and other components of ... smarter than we give them credit for, in that ...
(Date:9/22/2014)... a way to create a highly sensitive chemical sensor ... imperfections have unique electronic properties that the researchers were ... molecules by 300 times. , The study is available ... . , Amin Salehi- Khojin, asst professor of mechanical ... graduate student and Bijandra Kumar, post doc where they ...
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 years ... suffering, restoring hope an quality of life and contributing ... because of the innovative cellular biomedicines research that made ... , The company was founded in 1994 in ... chief of research, and Topricin inventor), Aurora Paradise (COO) ...
(Date:9/22/2014)... 2014 Invisible Sentinel Inc., a ... food and beverage industries, announced today that its ... a non-exclusive agreement by Enartis, a global provider ... an Esseco Group company headquartered in Trecate, Italy, ... and other global markets for their own in-winery ...
Breaking Biology Technology:Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3
... Matrox Graphics Inc., the leading,manufacturer of specialized ... Matrox Xenia(TM) Series display controller boards with its,ME/CCL ... first native PCI Express single-slot board with,all-digital, triple-monitor ... configuration. Xenia Series supports resolutions from <1MP to,8MP ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today ... presentation of favorable data,generated by scientists at Amgen, ... scheduled presentation by Dr. Paul Pevsner of the,NYU ... in identifying potential protein,biomarkers in colon cancer samples, ...
... 8 Transcept Pharmaceuticals,Inc., a privately-held specialty pharmaceutical ... President and Chief Financial Officer,is scheduled to present ... in New York City on Monday, October 13, ... webcast of the presentation will be available at, ...
Cached Biology Technology:Totoku Europe Chooses Matrox Xenia(TM) Series to Drive Medical Monitors 2Pressure BioSciences, Inc. Provides Corporate Update 2Pressure BioSciences, Inc. Provides Corporate Update 3Pressure BioSciences, Inc. Provides Corporate Update 4Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2
(Date:9/22/2014)... Yale University researchers are studying a potential new treatment ... disease in which scars develop in the lungs and ... mimic, miR-29, which is delivered to lung tissue intravenously. ... it reversed fibrosis after several days. , The ... EMBO Molecular Medicine . , "The mimic, when injected ...
(Date:9/22/2014)... Rochelle, NY, September 22, 2014Cassava, also known as tapioca, ... yields in areas of Africa, Asia, and Latin America ... the availability of novel enzymes and processes designed to ... be used to produce sweeteners such as glucose, fructose, ... to corn, as described in a Review article in ...
(Date:9/22/2014)... Antarctic fishes that manufacture their own "antifreeze" ... also suffer an unfortunate side effect, researchers report: ... bodies resist melting even when temperatures warm. ... Proceedings of the National Academy of Sciences . ... undesirable consequence of the evolution of antifreeze proteins ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... single dose of gene-virus combination cured rats of a ... causes the accumulation of bilirubin –which, untreated, results in ... of Medicine in a report in the Proceedings of ... first time this disease (Crigler-Najjar syndrome) has been completely ...
... new approach to predict whether a drug in development ... could get antibiotics to market faster and more cheaply, ... scientists worldwide have sounded the alarm: There simply aren’t ... adept at outwitting the traditional antibiotic arsenal. , Yet ...
... variation that may increase susceptibility to osteoporosis, a new study ... Louis demonstrated that in women the variant gene speeds up ... in the bones of the hip. , The study will ... Bone and Mineral Research and is available online. , ...
Cached Biology News:Gene Therapy Cures Inherited Liver Disease In Rats 2New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 2New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 3New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 4Increased risk of osteoporosis associated with gene that one in five people have 2
...
Ras-related C3 botulinum toxin substrate 1...
Human sVCAM-1/CD106 ELI-PAIR Kit...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: